CALDARET

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H16N2O3S
Molecular Weight	256.321
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O

InChI

InChIKey=DCDFLGVJWQIRGH-UHFFFAOYSA-N

InChI=1S/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C11H16N2O3S
Molecular Weight	256.321
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00078013 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19970618&CC=EP&NR=0779283A1&KC=A1 | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20030213&CC=WO&NR=03011296A1&KC=A1

Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction

Originator

Approval Year

PubMed

Title	Date	PubMed
Breast-feeding may reduce later blood pressure.	2004 Mar 16	15023898

Patents

Sample Use Guides

In Vivo Use Guide

4.5 mg/kg/48 hours

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:39:12 GMT 2023` Edited by `admin` on `Fri Dec 15 16:39:12 GMT 2023`
Record UNII	9L3Y3IJ2HI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALDARET

Official Name

English

caldaret [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333